Ductal Carcinoma in Situ of the Breast
March 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Predictive factors of invasion in ductal carcinoma in situ diagnosed by core-needle biopsy.
Authors:Villegas-Carlos F, Andino-Araque V, Valverde-Quintana M, Larios-Cruz KY, Pérez-González Y, Solano-Pérez JJ, Ruvalcaba-Limón E
Institution:Department of Breast Surgical Oncology, Fundacion del Cancer de Mama A.C. (FUCAM), Mexico City, Mexico.
Journal:Cir Cir. 2022;90(1):41-49. doi: 10.24875/CIRU.21000136.

2:Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy.
Authors:Rodin D, Sutradhar R, Nofech-Mozes S, Gu S, Faught N, Hahn E, Fong C, Trebinjac S, Paszat L, Rakovitch E
Institution:Radiation Medicine Program, Princess Margaret Cancer Centre, 700 University Avenue, Room 7-611, Toronto, ON, M4R 1M3, Canada. danielle.rodin@rmp.uhn.ca. Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Journal:Breast Cancer Res Treat. 2022 Feb;192(1):223-233. doi: 10.1007/s10549-021-06488-x. Epub 2022 Jan 27.

3:Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.
Authors:Maxwell AJ, Hilton B, Clements K, Dodwell D, Dulson-Cox J, Kearins O, Kirwan C, Litherland J, Mylvaganam S, Provenzano E, Pinder SE, Sawyer E, Shaaban AM, Sharma N, Stobart H, Wallis MG, Thompson AM
Institution:Nightingale Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Southmoor Road, Manchester, M23 9LT, UK; Division of Informatics, Imaging & Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, UK. Electronic address: anthony.maxwell@manchester.ac.uk. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA. Electronic address: alastair.thompson@bcm.edu.
Journal:Breast. 2022 Feb;61:145-155. doi: 10.1016/j.breast.2022.01.001. Epub 2022 Jan 4.

4:The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study.
Authors:Takada K, Kashiwagi S, Asano Y, Goto W, Morisaki T, Shibutani M, Tanaka H, Hirakawa K, Ohira M
Institution:Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.
Journal:Anticancer Res. 2022 Jan;42(1):311-320. doi: 10.21873/anticanres.15487.

5:Local Recurrence after Treatment of Ductal Carcinoma In Situ: A Comprehensive Overview.
Authors:Chiorescu A, Fredholm H, Sackey HI, Fredriksson I
Institution:
Journal:Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S128-S135. doi: 10.21614/chirurgia.116.5.suppl.S128.

6:Breast Reconstruction after Surgical Treatment of Ductal Carcinoma In Situ.
Authors:Bottoni M, Gottardi A, Rietjens M
Institution:
Journal:Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S88-S96. doi: 10.21614/chirurgia.116.5.suppl.S88.

7:The Natural History of Ductal Carcinoma In Situ of the Breast - An Overview.
Authors:Fredholm H, Chiorescu A, Fredriksson I, Sackey H
Institution:
Journal:Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S7-S14. doi: 10.21614/chirurgia.116.5.suppl.S7.

8:Overall and cancer-specific survival in patients with breast Paget disease: A population-based study.
Authors:Hu T, Chen Z, Hou M, Lin K
Institution:Department of Chemoradiation Oncology, 89657The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Experimental Center of Basic Medicine, 26453Wenzhou Medical University, Wenzhou 325000, China.
Journal:Exp Biol Med (Maywood). 2022 Feb;247(3):187-199. doi: 10.1177/15353702211056264. Epub 2021 Nov 29.

9:Single institute experience of intraoperative radiation therapy in early-stage breast cancer.
Authors:Chi MS, Ko HL, Chen CC, Hsu CH, Chen LK, Cheng FT
Institution:Department of Radiation Therapy and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. Department of General Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Journal:Medicine (Baltimore). 2021 Nov 19;100(46):e27842. doi: 10.1097/MD.0000000000027842.

10:The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
Authors:Ploumen RAW, Keymeulen KBMI, Kooreman LFS, van Kuijk SMJ, Siesling S, Smidt ML, van Nijnatten TJA
Institution:Department of Surgery, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, 6200 MD, Maastricht, the Netherlands. Electronic address: r.ploumen@maastrichtuniversity.nl. Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre+, 6202 AZ, Maastricht, the Netherlands. Electronic address: thiemo.nijnatten@mumc.nl.
Journal:Eur J Surg Oncol. 2022 Jan;48(1):60-66. doi: 10.1016/j.ejso.2021.10.016. Epub 2021 Oct 22.

11:Underestimation of invasive breast carcinoma in patients with initial diagnosis of ductal carcinoma in situ: Size matters.
Authors:Bouzón Alejandro A, Iglesias López Á, Acea Nebril B, García Jiménez ML, Díaz Carballada CC, Varela Romero JR
Institution:Department of Surgery, Breast Unit, Complejo Hospitalario Universitario A Coruna, Spain. Electronic address: dr.alberto@aecirujanos.es. Department of Radiology, Breast Unit, Complejo Hospitalario Universitario A Coruna, Spain.
Journal:Cir Esp (Engl Ed). 2021 Nov;99(9):655-659. doi: 10.1016/j.cireng.2021.02.006. Epub 2021 Feb 13.

12:Safety and Effectiveness of Areola-sparing Mastectomy for Breast Cancer With Intraductal Lesions.
Authors:Tokisawa H, Aruga T, Honda Y, Ishiba T, Yonekura R, Iwamoto N, Kumaki Y, Tomita S, Fujii M, Terao Y
Institution:Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan; miyamoto-h3836@cick.jp. Department of Plastic and Reconstructive Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan.
Journal:Anticancer Res. 2021 Nov;41(11):5723-5728. doi: 10.21873/anticanres.15388.

13:Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer.
Authors:Schermers B, van Riet YE, Schipper RJ, Vrancken Peeters MJ, Voogd AC, Nieuwenhuijzen GAP, Ten Haken B, Ruers TJM
Institution:Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Journal:Br J Surg. 2021 Dec 17;109(1):53-60. doi: 10.1093/bjs/znab339.

14:Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic.
Authors:Williams AD, Chang C, Sigurdson ER, Wang CH, Aggon AA, Hill MV, Porpiglia A, Bleicher RJ
Institution:Department of Surgery, Lankenau Medical Center, Wynnewood, PA, USA. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. richard.bleicher@fccc.edu.
Journal:Ann Surg Oncol. 2022 Mar;29(3):1683-1691. doi: 10.1245/s10434-021-10883-5. Epub 2021 Oct 11.

15:Factors involved in treatment decision making for women diagnosed with ductal carcinoma in situ: A qualitative study.
Authors:Hatton A, Heriot N, Zalcberg J, Ayton D, Evans J, Roder D, Chua BH, Hersch J, Lippey J, Fox J, Saunders C, Mann GB, Synnot J, Bell RJ
Institution:Cancer Research Program, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, Victoria, 3004, Australia. University, 553 St Kilda Rd, Melbourne, Victoria, 3004, Australia. University, 553 St Kilda Rd, Melbourne, Victoria, 3004, Australia; Medical Oncology Unit, Alfred Health, 55 Commercial Rd, Melbourne, Victoria, 3004, Australia. University, 553 St Kilda Rd, Melbourne, Victoria, 3004, Australia. Australia. Victoria, Australia. Australia. Monash University, 553 St Kilda Rd, Melbourne, Victoria, 3004, Australia. Electronic address: robin.bell@monash.edu.
Journal:Breast. 2021 Dec;60:123-130. doi: 10.1016/j.breast.2021.09.007. Epub 2021 Oct 1.

16:Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.
Authors:O'Keefe TJ, Harismendy O, Wallace AM
Institution:Division of Breast Surgery and The Comprehensive Breast Health Center, University of California San Diego, 0819, 3855 Health Sciences Dr, La Jolla, CA, 92037, USA. tokeefe@health.ucsd.edu.
Journal:Int J Clin Oncol. 2022 Jan;27(1):121-130. doi: 10.1007/s10147-021-02036-1. Epub 2021 Oct 7.

17:Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
Authors:Warren LEG, Bellon JR
Institution:Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
Journal:J Clin Oncol. 2021 Nov 10;39(32):3535-3540. doi: 10.1200/JCO.21.01896. Epub 2021 Oct 6.

18:Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
Authors:van Seijen M, Lips EH, Fu L, Giardiello D, van Duijnhoven F, de Munck L, Elshof LE, Thompson A, Sawyer E, Ryser MD, Hwang ES, Schmidt MK, Elkhuizen PHM, Wesseling J, Schaapveld M
Institution:Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Journal:Br J Cancer. 2021 Nov;125(10):1443-1449. doi: 10.1038/s41416-021-01496-6. Epub 2021 Aug 18.

19:Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
Authors:McCormick B, Winter KA, Woodward W, Kuerer HM, Sneige N, Rakovitch E, Smith BL, Germain I, Hartford AC, O'Rourke MA, Walker EM, Strom EA, Hopkins JO, Pierce LJ, Pu AT, Sumida KNM, Vesprini D, Moughan J, White JR
Institution:Memorial Sloan Kettering Cancer Center, New York, NY. Ohio State University Comprehensive Cancer Center, Columbus, OH.
Journal:J Clin Oncol. 2021 Nov 10;39(32):3574-3582. doi: 10.1200/JCO.21.01083. Epub 2021 Aug 18.

20:Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor.
Authors:Hwang KT, Suh YJ, Park CH, Lee YJ, Kim JY, Jung JH, Kim S, Min J
Institution:Department of Surgery, Seoul National University College of Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea. Department of Surgery, Dankook University College of Medicine, Cheonan, Republic of Korea.
Journal:Oncologist. 2021 Nov;26(11):e1939-e1950. doi: 10.1002/onco.13938. Epub 2021 Sep 2.

21:Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions.
Authors:Lamb LR, Bahl M
Institution:Massachusetts General Hospital, 55 Fruit St, WAC 240, Boston, MA 02114.
Journal:AJR Am J Roentgenol. 2022 Jan;218(1):186-187. doi: 10.2214/AJR.21.26340. Epub 2021 Jul 21.

22:Effect of the Ductal Carcinoma In Situ Margin Consensus Guideline Implementation on Re-Excision Rates, Satisfaction, and Cost.
Authors:Bhutiani N, Holland MM, Mercer MK, Donaldson M, Berry TS, McMasters KM, Ajkay N
Institution:Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, USA. Louisville, KY, USA. Louisville, KY, USA. Louisville, KY, USA. USA. Louisville, KY, USA. Louisville, KY, USA. Nicolas.ajkay@louisville.edu.
Journal:Ann Surg Oncol. 2021 Nov;28(12):7432-7438. doi: 10.1245/s10434-021-10120-z. Epub 2021 May 27.

23:Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
Authors:Yan M, Bomeisl P, Gilmore H, Harbhajanka A
Institution:24575University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Journal:Int J Surg Pathol. 2021 Dec;29(8):836-843. doi: 10.1177/10668969211012088. Epub 2021 Apr 23.

24:Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.
Authors:Chapman BM, Yang JC, Gonzalez JM, Havrilesky L, Reed SD, Hwang ES
Institution:Duke University School of Medicine, Durham, NC.
Journal:JCO Oncol Pract. 2021 Nov;17(11):e1639-e1648. doi: 10.1200/OP.20.00614. Epub 2021 Mar 12.

For a FREE PREVIEW of the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast...
at a Special 20% Discount


Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast

Updated: January 3, 2022
160 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $49.95
  • Less 20% Discount = - $10.00
  • Discounted Price = $39.95(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $34.95
  • Less 20% Discount = - $7.00
  • Discounted Price = $27.95

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

DC940402278

Coupon Expires: September 13, 2022



What Our Customers Are Saying...

"The MediFocus Guidebook on DCIS was more than adequate for my research on this condition and I would recommend it to anyone wanting the "whole picture". Thank you for providing this excellent service."
C.M.
Los Angeles, California


"At a very difficult time, your MediFocus Guidebook on Ductal Carcinoma in Situ helped our family make informed decisions. Thank you for your help!"
M.A.L.
Metarie, Louisiana


"I was recently diagnosed with DCIS and was looking everywhere for information to get myself educated. The MediFocus Guidebook was very helpful in clarifying everything for me. The information is so well organized that it makes it easy to read and understand. I feel much better now that I've read this Guidebook and have a clearer understanding of the issues that I face. I highly recommend this Guidebook to anyone seeking to understand DCIS."
C.G.
Ft. Lauderdale, Florida



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2022 Medifocus, Inc. All rights reserved.